Tocilizumab-Atlizumab Overview - Creative Biolabs
Anti‐interleukin‐6 receptor antibody, tocilizumab, for the treatment of autoimmune diseases - Tanaka - 2011 - FEBS Letters - Wiley Online Library
Tocilizumab: A Therapeutic Option for the Treatment of Cytokine Storm Syndrome in COVID-19 - ScienceDirect
Interleukin-6 inhibition in the management of non-infectious uveitis and beyond | Journal of Ophthalmic Inflammation and Infection | Full Text
Mechanism of action of tocilizumab in RA (bathtub theory). Notes: The... | Download Scientific Diagram
Interleukin‑6 signaling blockade treatment for cytokine release syndrome in COVID‑19 (Review)
Why tocilizumab could be an effective treatment for severe COVID-19? | Journal of Translational Medicine | Full Text
Tocilizumab in the treatment of adult rheumatoid arthritis | Immunotherapy
Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial | The BMJ
Rational Use of Tocilizumab in the Treatment of Novel Coronavirus Pneumonia | SpringerLink
Role of IL-6 inhibitor in treatment of COVID-19-related cytokine release syndrome
Treatment of Rheumatoid Arthritis with Biological Agents | IntechOpen
IJMS | Free Full-Text | Therapeutic Role of Tocilizumab in SARS-CoV-2-Induced Cytokine Storm: Rationale and Current Evidence | HTML
Low immunogenicity of tocilizumab in patients with rheumatoid arthritis | Annals of the Rheumatic Diseases
Why tocilizumab could be an effective treatment for severe COVID-19? | Journal of Translational Medicine | Full Text
Tocilizumab for treatment patients with COVID-19: Recommended medication for novel disease - ScienceDirect
Actemra | Uses, Safety Info & Comparison to Other RA Drugs
Frontiers | Potential Benefits of Tryptophan Metabolism to the Efficacy of Tocilizumab in COVID-19 | Pharmacology
![The efficacy of IL-6 inhibitor Tocilizumab in reducing severe COVID-19 mortality: a systematic review [PeerJ]](https://dfzljdn9uc3pi.cloudfront.net/2020/10322/1/fig-3-full.png "The efficacy of IL-6 inhibitor Tocilizumab in reducing severe COVID-19 mortality: a systematic review [PeerJ]")
The efficacy of IL-6 inhibitor Tocilizumab in reducing severe COVID-19 mortality: a systematic review [PeerJ]
Frontiers | Tocilizumab: The Key to Stop Coronavirus Disease 2019 (COVID-19)-Induced Cytokine Release Syndrome (CRS)? | Medicine
JCI - IL-6 polymorphisms: a useful genetic tool for inflammation research?
Frontiers | Current Evidence of Interleukin-6 Signaling Inhibitors in Patients With COVID-19: A Systematic Review and Meta-Analysis | Pharmacology
A Review of Recent Advances Using Tocilizumab in the Treatment of Rheumatic Diseases | SpringerLink
Figure 5 | The Roles of Interleukin-6 in the Pathogenesis of Rheumatoid Arthritis
Immunomodulation as a potent COVID-19 pharmacotherapy | JIR
Tocilizumab Raises GI Risks in Rheumatoid Arthritis | MedPage Today
Clinical experience of IL-6 blockade in rheumatic diseases—Implications on IL-6 biology and disease pathogenesis - ScienceDirect
Subcutaneous formulation of tocilizumab for treatment of rheumatoid arthritis | Therapeutic Delivery
